|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.65M
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 44K
3: EX-10.34 Material Contract HTML 77K
4: EX-10.46 Material Contract HTML 61K
5: EX-21.1 Subsidiaries List HTML 27K
6: EX-23 Consent of Expert or Counsel HTML 27K
11: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 47K
Awarded Compensation
7: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 30K
17: R1 Document and Entity Information HTML 99K
18: R2 Consolidated Balance Sheets HTML 124K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
20: R4 Consolidated Statements of Net Loss and HTML 104K
Comprehensive Loss
21: R5 Consolidated Statements of Changes in HTML 75K
Stockholders' Equity
22: R6 Consolidated Statements of Cash Flows HTML 92K
23: R7 Organization and Description of Business HTML 31K
24: R8 Basis of Presentation HTML 34K
25: R9 Summary of Significant Accounting Policies HTML 116K
26: R10 Product Revenue, Net HTML 75K
27: R11 Net Loss Per Share HTML 44K
28: R12 Inventories HTML 59K
29: R13 Intangible Assets, Net HTML 32K
30: R14 Accrued Liabilities HTML 47K
31: R15 License Agreements and Commitments HTML 161K
32: R16 Stockholders' Equity HTML 39K
33: R17 Stock-Based Compensation HTML 110K
34: R18 Income Taxes HTML 131K
35: R19 Other Benefits HTML 30K
36: R20 Restructuring Charge HTML 32K
37: R21 Summary of Significant Accounting Policies HTML 167K
(Policies)
38: R22 Summary of Significant Accounting Policies HTML 73K
(Tables)
39: R23 Product Revenue, Net (Tables) HTML 70K
40: R24 Net Loss Per Share (Tables) HTML 43K
41: R25 Inventories (Tables) HTML 58K
42: R26 Accrued Liabilities (Tables) HTML 47K
43: R27 License Agreements and Commitments (Tables) HTML 132K
44: R28 Stock-Based Compensation (Tables) HTML 100K
45: R29 Income Taxes (Tables) HTML 136K
46: R30 BASIS OF PRESENTATION - Accumulated deficit HTML 31K
(Details)
47: R31 BASIS OF PRESENTATION - Cash and cash equivalents HTML 30K
(Details)
48: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 36K
Concentration of Credit Risk (Details)
49: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 29K
Inventories (Details)
50: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 45K
Value Measurements (Details)
51: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 56K
Revenue Recognition - License revenue (Details)
52: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Segment Information (Details)
53: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 43K
Property and Equipment (Details)
54: R38 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 29K
Provision for Income Taxes (Details)
55: R39 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other HTML 33K
policies (Details)
56: R40 PRODUCT REVENUE NET - Disaggregation (Details) HTML 46K
57: R41 PRODUCT REVENUE, NET - Concentrations (Details) HTML 53K
58: R42 PRODUCT REVENUE, NET - Receivables, allowances and HTML 41K
accrued liabilities (Details)
59: R43 PRODUCT REVENUE, NET - Reserves for discounts and HTML 71K
allowances (Details)
60: R44 NET LOSS PER SHARE - Basic and diluted (Details) HTML 55K
61: R45 NET LOSS PER SHARE - Anti-dilutive securities HTML 30K
(Details)
62: R46 Inventories (Details) HTML 47K
63: R47 Intangible Assets, Net (Details) HTML 58K
64: R48 Accrued Liabilities (Details) HTML 41K
65: R49 LICENSE AGREEMENTS AND COMMITMENTS - MSK License HTML 40K
Agreement (Details)
66: R50 LICENSE AGREEMENTS AND COMMITMENTS - CD33 License HTML 38K
(Details)
67: R51 LICENSE AGREEMENTS AND COMMITMENTS - MabVax/MSK HTML 34K
License (Details)
68: R52 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 45K
Agreement (Details)
69: R53 LICENSE AGREEMENTS AND COMMITMENTS - Summary of HTML 61K
Significant Agreements and Commitments (Details)
70: R54 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 48K
agreements (Details)
71: R55 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 51K
agreements (Details)
72: R56 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 37K
(Details)
73: R57 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 42K
maturities (Details)
74: R58 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 32K
and discount rate (Details)
75: R59 LICENSE AGREEMENTS AND COMMITMENTS - Severance HTML 39K
Related Benefits (Details)
76: R60 LICENSE AGREEMENTS AND COMMITMENTS - Legal matters HTML 36K
(Details)
77: R61 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 47K
Preferred Stock (Details)
78: R62 STOCKHOLDERS' EQUITY - Stock Grant Agreements with HTML 90K
Non-Employees (Details)
79: R63 STOCK-BASED COMPENSATION - 2015 Plan (Details) HTML 41K
80: R64 STOCK-BASED COMPENSATION - 2018 Plan (Details) HTML 64K
81: R65 STOCK-BASED COMPENSATION - Stock-based HTML 47K
compensation expense - Options (Details)
82: R66 STOCK-BASED COMPENSATION - Stock Option Valuation HTML 36K
(Details)
83: R67 STOCK-BASED COMPENSATION - Stock option activity HTML 70K
(Details)
84: R68 STOCK-BASED COMPENSATION - Stock option grants HTML 82K
(Details)
85: R69 STOCK-BASED COMPENSATION - Stock option HTML 33K
unrecognized compensation (Details)
86: R70 STOCK-BASED COMPENSATION - Restricted Stock Units HTML 76K
(Details)
87: R71 INCOME TAXES - Loss before income taxes (Details) HTML 37K
88: R72 INCOME TAXES - Current and deferred income taxes HTML 50K
(Details)
89: R73 INCOME TAXES - Reconciliation of Income Taxes HTML 58K
(Details)
90: R74 INCOME TAXES - Deferred assets (Liabilities) HTML 57K
(Details)
91: R75 INCOME TAXES - Net Operating Loss Carryforwards HTML 39K
(Details)
92: R76 INCOME TAXES - Unrecognized tax benefits (Details) HTML 34K
93: R77 Other Benefits (Details) HTML 33K
94: R78 Restructuring Charge (Details) HTML 45K
95: R79 Pay vs Performance Disclosure HTML 40K
96: R80 Insider Trading Arrangements HTML 34K
98: XML IDEA XML File -- Filing Summary XML 175K
101: XML XBRL Instance -- ymab-20231231x10k_htm XML 1.95M
97: EXCEL IDEA Workbook of Financial Report Info XLSX 170K
13: EX-101.CAL XBRL Calculations -- ymab-20231231_cal XML 169K
14: EX-101.DEF XBRL Definitions -- ymab-20231231_def XML 760K
15: EX-101.LAB XBRL Labels -- ymab-20231231_lab XML 1.46M
16: EX-101.PRE XBRL Presentations -- ymab-20231231_pre XML 1.19M
12: EX-101.SCH XBRL Schema -- ymab-20231231 XSD 223K
99: JSON XBRL Instance as JSON Data -- MetaLinks 523± 803K
100: ZIP XBRL Zipped Folder -- 0001558370-24-002188-xbrl Zip 706K
EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Rossi certify that:
| 1. | I have reviewed this Annual Report on Form 10-K of Y-mAbs Therapeutics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| |
Date: February 29, 2024 | |
| /s/ Michael Rossi |
| Name: Michael Rossi |
| Title: President, Chief Executive Officer |
| (Principal Executive Officer) |
1
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/29/24 | 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/07/24 Y-mAbs Therapeutics, Inc. 10-Q 3/31/24 86:8.2M Toppan Merrill Bridge/FA 2/29/24 Y-mAbs Therapeutics, Inc. S-8 2/29/24 4:185K Toppan Merrill Bridge/FA |